Law Office of Brodsky & Smith, LLC Announces Investigation of MAP Pharmaceuticals, Inc.
26 Janvier 2013 - 6:00PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
MAP Pharmaceuticals, Inc. (“MAP” or the “Company”) (Nasdaq: MAPP)
relating to the proposed acquisition by Allergan, Inc.
(“Allergan”).
Under the terms of the transaction, MAP shareholders will
receive only $25.00 in cash for each share of MAP stock they own.
The investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of MAP for
not acting in the Company’s shareholders' best interests in
connection with the sale process to Allergan. MAP is expected to
receive a decision on its inhalable migraine treatment Levadex by
the Food and Drug Administration before mid-April. It has been
reported that the global migraine drug market will reach $5.8
billion by 2021.
If you own shares of MAP stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/530-mapp-map-pharmaceuticals-inc.html, by
calling toll free 877-LEGAL-90.
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Map Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Brodsky & Smith, LLC